|
|
|
|
Dr. Eli Lewis Joins the Omni Bio Pharmaceutical Scientific Advisory Board
- Dr.Eli Lewis, a director of the Clinical Islet Laboratory with Ben-Gurion University of the Negev, Israel, has accepted a position on the Scientific Advisory Board of Omni Bio Pharmaceutical, Inc. ('OMNI') (OTCBB: AAFS) In October...
|
|
|
Biomarkers of AAA progression. Part 1: extracellular matrix degeneration
AbstractAbdominal aortic aneurysm (AAA) is an important health problem.Elective surgical treatment is recommended on the basis of an individual's risk of rupture, which is predicted by AAA diameter. However, the natural history of AAA...
Nature Clinical Practice Cardiovascular Medicine:
Jun 25 2009 10:27AM
Matching: 1 antitrypsin
|
Find similar documents
|
|
|
|
Alpha1-Antitrypsin Deficiency
_ Alpha1-Antitrypsin Deficiency.
|
|
|
Dr. Eli Lewis Joins the Omni Bio Pharmaceutical Scientific Advisory Board
Eli Lewis, a director of the Clinical Islet Laboratory with Ben-Gurion University of the Negev, Israel, has accepted a position on the Scientific Advisory Board of Omni Bio Pharmaceutical, Inc.('OMNI') (OTCBB: AAFS) In October 2008, Dr.
|
|
|
Omni Bio Pharmaceutical: Dr. Eli Lewis Joins the Omni Bio Pharmaceutical Scientific Advisory Board
SOURCE: Omni Bio Pharmaceutical DENVER, CO--(Marketwire - June 24, 2009) - Dr.Eli Lewis, a director of the Clinical Islet Laboratory with Ben-Gurion University of the Negev, Israel, has accepted a position on the Scientific Advisory Board...
|
|
|
Dr. Eli Lewis Joins the Omni Bio Pharmaceutical Scientific
Eli Lewis, a director of the Clinical Islet Laboratory with Ben-Gurion University of the Negev, Israel, has accepted a position on the Scientific Advisory Board of Omni Bio Pharmaceutical, Inc.('OMNI') (OTCBB: AAFS) In October 2008, Dr.
|
|
|
Dr. Eli Lewis Joins the Omni Bio Pharmaceutical Scientific Advisory Board
Eli Lewis, a director of the Clinical Islet Laboratory with Ben-Gurion University of the Negev, Israel, has accepted a position on the Scientific Advisory Board of Omni Bio Pharmaceutical, Inc.('OMNI') (OTC.BB: AAFS) In October 2008, Dr....
|
|
|
Dr. Eli Lewis Joins the Omni Bio Pharmaceutical Scientific Advisory Board
In October 2008, Dr.Lewis co-published a study in the Proceedings of the National Academy of Sciences with OMNI Acting Chief Executive Officer Dr. Charles A. Dinarello and University of Colorado researcher Dr. Leland Shapiro titled ...
|
|
|
Dr. Eli Lewis Joins the Omni Bio Pharmaceutical Scientific Advisory Board
- Dr.Eli Lewis, a director of the Clinical Islet Laboratory with Ben-Gurion University of the Negev, Israel, has accepted a position on the Scientific Advisory Board of Omni Bio Pharmaceutical, Inc. ('OMNI') (OTCBB In October 2008, Dr....
|
|
|
Urinary Peptide Patterns in Native Kidneys and Kidney Allografts
Background.The use of biopsies to determine kidney health after kidney transplantation is an invasive procedure with some risk to the patient. Consequently, a noninvasive test for transplanted kidney health would provide a significant...
|
|
|
Cluster headache and alpha 1-antitrypsin deficiency
No association found between CH and a genotype not matching the homozygous wild type for alpha-1-AT Significant difference of CH attack frequency in pts who are Cluster headache and alpha 1-antitrypsin...
|
|
|
Alpha-1 Foundation Announces the Million Dollar Match Program Made Possible by a Talecris Biotherapeutics Gran
The Talecris grant matches every dollar the Foundation raises in donations for research, up to one million dollars.Talecris developed and manufactures Prolastin (Alpha1-Proteinase Inhibitor [Human]), a leading treatment for alpha1-...
|
|
|
Kamada Reports Positive Proof-of-Concept Data for Inhaled Alpha-1 Antitrypsin in Bronchiectasis
The results indicate that Inhaled AAT, via an optimized eFlow platform nebulizer (PARI Pharma GmbH), provides a positive indication as to its ability to decrease the inflammatory process in the lung.Furthermore, as reported previously,...
|
|
|
Kamada Reports Positive Proof-of-Concept Data for Inhaled Alpha-1 Antitrypsin in Bronchiectasis
NESS ZIONA, Israel - (BUSINESS WIRE) - Kamada (TASE:KMDA), a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today positive proof of concept data from a...
|
|
|
Kamada Reports Positive Proof-of-Concept Data for Inhaled Alpha-1 Antitrypsin in Bronchiectasis
- Kamada (TASE:KMDA), a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today positive proof of concept data from a phase II, proof of concept study with its...
|
|
|
Kamada Reports Positive Proof-of-Concept Data for Inhaled Alpha-1 Antitrypsin in Bronchiectasis
Kamada (TASE:KMDA), a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today positive proof of concept data from a phase II, proof of concept study with its...
|
|
|
Kamada Ltd. Reports Positive Proof-of-Concept Data for Inhaled Alpha-1 Antitrypsin in Bronchiectasis
NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada (TASE:KMDA), a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today positive proof of concept data from a phase...
|
|
|
Alpha-1 Foundation Announces the Million Dollar Match Program Made Possible by a Talecris Biotherapeutics Gran
The Alpha-1 Foundation announced today it will receive up to $1 million in grant matching funds from Talecris Biotherapeutics, Inc.to support research into alpha1-antitrypsin deficiency, a genetic condition in which low...
|
|
|
'Missteps' Can Spell Liver Failure In Children With Genetic Disease
Two genetic missteps can put an infant with a genetic defect called alpha-1 antitrypsin deficiency on the road to rapid liver failure, said researchers from Baylor College of Medicine and the University of Florida in a...
|
|
|
Kamada Submits U.S. Biologics License Application for the First Liquid, Ready to Use AAT for the Treatment of
- Kamada (TASE:KMDA) a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced that it has submitted a Biologics License Application (BLA) to the U.S.Food and...
|
|
|
Kamada Submits U.S. Biologics License Application for the First Liquid, Ready to Use AAT for the Treatment of
Kamada (TASE:KMDA) ' a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced that it has submitted a Biologics License Application (BLA) to the U.S.Food and...
|
|
|
Lung function in 30-year-old alpha-1-antitrypsin-deficient individuals
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Respiratory Medicine, 06/01/09 Print Save in My Library Free Abstract Bernspang E et al.- AAT-deficient individuals identified by neonatal screening have...
|
|
|
Augmentation Therapy for alpha-1 Antitrypsin Deficiency: A Meta-Analysis
(Click the title below to leave the MDLinx Network and go to the Journal's Website) COPD: Journal of Chronic Obstructive Pulmonary Disease, 05/29/09 Print Save in My Library Free Abstract Chapman KR et al.- This meta-analysis supports the...
|
|
|
FTC Authorizes Suit To Stop CSLs Proposed $3.1 Billion Acquisition of Talecris Biotherapeutics
-The Federal Trade Commission has authorized a lawsuit to block CSL Limited’s proposed $3.1 billion acquisition of Talecris Biotherapeutics Holdings Corporation, charging that the deal would be illegal and would substantially...
|
|
|
Talecris data shows that concentrated form of Prolastin is safe and tolerable; potentially cuts infusion times
Talecris Biotherapeutics presented results last week from two phase III studies assessing the safety, tolerability and pharmacokinetic comparability of a more concentrated formulation of Prolastin (Alpha1-Proteinase Inhibitor [Human])...
|
